

# Pierre Sokoloff

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10411955/publications.pdf>

Version: 2024-02-01

81  
papers

11,805  
citations

53939

47  
h-index

75989

78  
g-index

83  
all docs

83  
docs citations

83  
times ranked

6813  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Historical Perspective on the Dopamine D3 Receptor. <i>Current Topics in Behavioral Neurosciences</i> , 2022, , 1-28.	0.8	1
2	Pharmacology profile of F17464, a dopamine D3 receptor preferential antagonist. <i>European Journal of Pharmacology</i> , 2021, 890, 173635.	1.7	17
3	The dopamine D3 receptor, a quarter century later. <i>European Journal of Neuroscience</i> , 2017, 45, 2-19.	1.2	178
4	Developmental and adult expression patterns of the Gâ€proteinâ€coupled receptor GPR88 in the rat: Establishment of a dual nuclearâ€cytoplasmic localization. <i>Journal of Comparative Neurology</i> , 2016, 524, 2776-2802.	0.9	17
5	A GIPC1-Palmitate Switch Modulates Dopamine Drd3 Receptor Trafficking and Signaling. <i>Molecular and Cellular Biology</i> , 2016, 36, 1019-1031.	1.1	14
6	Dopamine D3 receptor ligands for drug addiction treatment. <i>Progress in Brain Research</i> , 2014, 211, 255-275.	0.9	47
7	Direct and indirect interactions of the dopamine D3 receptor with glutamate pathways: implications for the treatment of schizophrenia. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2013, 386, 107-124.	1.4	38
8	Striatal GPR88 expression is confined to the whole projection neuron population and is regulated by dopaminergic and glutamatergic afferents. <i>European Journal of Neuroscience</i> , 2009, 30, 397-414.	1.2	78
9	Brain-derived neurotrophic factor-deficient mice exhibit a hippocampal hyperserotonergic phenotype. <i>International Journal of Neuropsychopharmacology</i> , 2008, 11, 79-92.	1.0	54
10	Dopamine D3receptor ligands for the treatment of tobacco dependence. <i>Expert Opinion on Investigational Drugs</i> , 2007, 16, 45-57.	1.9	38
11	N-(4-(4-(2-Halogenophenyl)piperazin-1-yl)butyl) Substituted Cinnamoyl Amide Derivatives as Dopamine D2and D3 Receptor Ligands. <i>Archiv Der Pharmazie</i> , 2007, 340, 178-184.	2.1	10
12	A functional variant of the dopamine D3 receptor is associated with risk and age-at-onset of essential tremor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 10753-10758.	3.3	183
13	A single cocaine exposure increases BDNF and D3 receptor expression: implications for drug-conditioning. <i>NeuroReport</i> , 2005, 16, 175-178.	0.6	165
14	Dopamine D3 Receptor Ligands Block Nicotine-Induced Conditioned Place Preferences through a Mechanism that does not Involve Discriminative-Stimulus or Antidepressant-Like Effects. <i>Neuropsychopharmacology</i> , 2005, 30, 720-730.	2.8	100
15	Neuroadaptations to hyperdopaminergia in dopamine D3 receptor-deficient mice. <i>Life Sciences</i> , 2005, 76, 1281-1296.	2.0	55
16	Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors. <i>Parkinsonism and Related Disorders</i> , 2005, 11, S25-S29.	1.1	113
17	The dopamine D receptor and drug dependence: Effects on reward or beyond?. <i>Neuropharmacology</i> , 2005, 49, 525-541.	2.0	166
18	Brain-Derived Neurotrophic Factor And The Plasticity Of The Mesolimbic Dopamine Pathway. <i>International Review of Neurobiology</i> , 2004, 59, 425-444.	0.9	39

#	ARTICLE	IF	CITATIONS
19	GIPC Recruits GAIP (RGS19) To Attenuate Dopamine D2 Receptor Signaling. <i>Molecular Biology of the Cell</i> , 2004, 15, 4926-4937.	0.9	67
20	Effect of the D3 Dopamine Receptor Partial Agonist BP897 [N-[4-(4-(2-Methoxyphenyl)piperazinyl)butyl]-2-naphthamide] on l-3,4-Dihydroxyphenylalanine-Induced Dyskinesias and Parkinsonism in Squirrel Monkeys. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 311, 770-777.	1.3	46
21	Interactions of GIPC with Dopamine D2, D3but not D4Receptors Define a Novel Mode of Regulation of G Protein-coupled Receptors. <i>Molecular Biology of the Cell</i> , 2004, 15, 696-705.	0.9	91
22	Subapical Localization of the Dopamine D3 Receptor in Proximal Tubules of the Rat Kidney. <i>Journal of Histochemistry and Cytochemistry</i> , 2004, 52, 1647-1655.	1.3	26
23	Dopamine and glutamate dysfunctions in schizophrenia: Role of the dopamine D3 receptor. <i>Neurotoxicity Research</i> , 2004, 6, 63-71.	1.3	20
24	Dopamine D3 receptor ligands modulate the acquisition of morphine-conditioned place preference. <i>Psychopharmacology</i> , 2004, 175, 127-33.	1.5	19
25	Development of Novel 1,2,3,4-Tetrahydroisoquinoline Derivatives and Closely Related Compounds as Potent and Selective Dopamine D3 Receptor Ligands. <i>ChemBioChem</i> , 2004, 5, 508-518.	1.3	85
26	Role of DRD3 in morphine-induced conditioned place preference using drd3-knockout mice. <i>NeuroReport</i> , 2004, 15, 2245-2249.	0.6	46
27	N-(1'--(4-(2-Methoxyphenyl)piperazin-1-yl)alkyl)carboxamides as Dopamine D2and D3Receptor Ligands. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 3883-3899.	2.9	100
28	Brain-derived neurotrophic factor controls dopamine D3 receptor expression: therapeutic implications in Parkinson's disease. <i>European Journal of Pharmacology</i> , 2003, 480, 89-95.	1.7	59
29	Increased dopamine D3 receptor expression accompanying behavioral sensitization to nicotine in rats. <i>Synapse</i> , 2003, 47, 176-183.	0.6	139
30	Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function. <i>Nature Medicine</i> , 2003, 9, 762-767.	15.2	370
31	The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade. <i>Neuropharmacology</i> , 2003, 45, 174-181.	2.0	75
32	A dopamine D3 receptor partial agonist blocks the expression of conditioned activity. <i>NeuroReport</i> , 2002, 13, 173-176.	0.6	28
33	Role of the dopamine D3receptor in reactivity to cocaine-associated cues in mice. <i>European Journal of Neuroscience</i> , 2002, 15, 2016-2026.	1.2	162
34	Brain-derived neurotrophic factor controls dopamine D3 receptor expression: Implications for neurodevelopmental psychiatric disorders. <i>Neurotoxicity Research</i> , 2002, 4, 671-678.	1.3	43
35	BDNF-Dependent Behavioral Sensitization in Hemiparkinsonian Rats. <i>Advances in Behavioral Biology</i> , 2002, , 365-368.	0.2	0
36	The dopamine D3 receptor and drug addiction. <i>Neurotoxicity Research</i> , 2001, 3, 433-441.	1.3	48

#	ARTICLE	IF	CITATIONS
37	Identification of the dopamine autoreceptor in the guinea-pig retina as D2 receptor using novel subtype-selective antagonists. <i>British Journal of Pharmacology</i> , 2001, 133, 1243-1248.	2.7	20
38	BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. <i>Nature</i> , 2001, 411, 86-89.	13.7	535
39	D2/D3 Dopamine Receptor Heterodimers Exhibit Unique Functional Properties. <i>Journal of Biological Chemistry</i> , 2001, 276, 30308-30314.	1.6	196
40	Role of dopamine D3 receptors in thermoregulation. <i>NeuroReport</i> , 2000, 11, 221-225.	0.6	42
41	Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned rats. <i>European Journal of Neuroscience</i> , 2000, 12, 2117-2123.	1.2	128
42	Dopamine D <sub>3</sub> Receptors Expressed by All Mesencephalic Dopamine Neurons. <i>Journal of Neuroscience</i> , 2000, 20, 8677-8684.	1.7	308
43	Heterocyclic congeners of PD 128,907 with a partially hydrogenated benzomorpholine moiety as potential dopamine D3-receptor ligands. <i>European Journal of Medicinal Chemistry</i> , 1999, 34, 791-798.	2.6	14
44	Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. <i>Nature</i> , 1999, 400, 371-375.	13.7	550
45	Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptors. <i>European Journal of Pharmacology</i> , 1999, 366, 293-300.	1.7	136
46	Title is missing!. <i>Nature</i> , 1999, 401, 403-403.	13.7	0
47	errata Selective inhibition of cocaine-seeking behaviour by a partial dopamine D3 receptor agonist. <i>Nature</i> , 1999, 401, 403-403.	13.7	5
48	D3 dopamine receptor mRNA is widely expressed in the human brain. <i>Brain Research</i> , 1998, 779, 58-74.	1.1	219
49	Meta-analysis of DRD3 gene and schizophrenia: Ethnic heterogeneity and significant association in caucasians. , 1998, 81, 318-322.		108
50	Coexpression of dopamine D1 and D3 receptors in islands of Calleja and shell of nucleus accumbens of the rat: opposite and synergistic functional interactions. <i>European Journal of Neuroscience</i> , 1998, 10, 1676-1686.	1.2	140
51	Functional implications of multiple dopamine receptor subtypes: the D1/D3 receptor coexistence 1. Published on the World Wide Web on 24 November 1997.1. <i>Brain Research Reviews</i> , 1998, 26, 236-242.	9.1	134
52	D3 receptor test in vitro predicts decreased cocaine self-administration in rats. <i>NeuroReport</i> , 1997, 8, 2373-2377.	0.6	137
53	Codistribution of the dopamine D3 receptor and glucocorticoid receptor mRNAs during striatal prenatal development in the rat. <i>Neuroscience Letters</i> , 1997, 227, 119-122.	1.0	20
54	Selective Expression of Dopamine D <sub>3</sub> Receptor mRNA in Proliferative Zones during Embryonic Development of the Rat Brain. <i>Journal of Neuroscience</i> , 1997, 17, 4282-4292.	1.7	117

#	ARTICLE	IF	CITATIONS
55	Two Intracellular Signaling Pathways for the Dopamine D <sub>3</sub> Receptor: Opposite and Synergistic Interactions with Cyclic AMP. <i>Journal of Neurochemistry</i> , 1997, 68, 1-9.	2.1	48
56	Dopamine-related genes and their relationships to monoamine metabolites in CSF. <i>Biological Psychiatry</i> , 1996, 40, 1032-1043.	0.7	95
57	Autoradiographic localisation of D <sub>3</sub> -dopamine receptors in the human brain using the selective D <sub>3</sub> -dopamine receptor agonist (+)-[ <sup>3</sup> H]PD 128907. <i>Psychopharmacology</i> , 1996, 128, 240-247.	1.5	115
58	Localization, Regulation, and Role of the Dopamine D <sub>3</sub> Receptor Are Distinct from Those of the D <sub>2</sub> Receptor. <i>Clinical Neuropharmacology</i> , 1995, 18, S130-S142.	0.2	23
59	A functional test identifies dopamine agonists selective for D <sub>3</sub> versus D <sub>2</sub> receptors. <i>NeuroReport</i> , 1995, 6, 329-332.	0.6	210
60	Clinical and functional correlates of a dopamine D <sub>3</sub> receptor polymorphism. <i>Human Psychopharmacology</i> , 1995, 10, 19-24.	0.7	9
61	The preferential dopamine D <sub>3</sub> receptor ligand, (+)-UH232, is a partial agonist. <i>European Journal of Pharmacology</i> , 1995, 282, R3-R4.	1.7	19
62	Novel Dopamine Receptor Subtypes as Targets for Antipsychotic Drugs. <i>Annals of the New York Academy of Sciences</i> , 1995, 757, 278-292.	1.8	16
63	The dopamine D <sub>3</sub> receptor and schizophrenia: pharmacological, anatomical and genetic approaches. <i>European Neuropsychopharmacology</i> , 1995, 5, 3-9.	0.3	34
64	Novel dopamine receptors half a decade later. <i>Trends in Pharmacological Sciences</i> , 1995, 16, 270-275.	4.0	262
65	Functional coupling of the human dopamine D <sub>3</sub> receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line. <i>European Journal of Pharmacology</i> , 1994, 268, 129-139.	2.7	122
66	No association between schizophrenia and homozygosity at the D <sub>3</sub> dopamine receptor gene. <i>American Journal of Medical Genetics Part A</i> , 1993, 48, 83-86.	2.4	69
67	Exclusion of close linkage of bipolar disorder to the dopamine D <sub>3</sub> receptor gene in nine Australian pedigrees. <i>Journal of Affective Disorders</i> , 1993, 27, 213-224.	2.0	22
68	No evidence of linkage between schizophrenia and D <sub>3</sub> dopamine receptor gene locus in Icelandic pedigrees. <i>Psychiatry Research</i> , 1993, 46, 69-78.	1.7	49
69	A serine to glycine substitution at position 9 in the extracellular N-terminal part of the dopamine D <sub>3</sub> receptor protein: No role in the genetic predisposition to bipolar affective disorder. <i>Psychiatry Research</i> , 1993, 46, 253-259.	1.7	52
70	Heterogeneity and regulation of central dopamine receptor subtypes studied by cDNA cloning methodology. <i>Neurochemistry International</i> , 1992, 20, 27-32.	1.9	5
71	The third dopamine receptor (D <sub>3</sub> ) as a novel target for antipsychotics. <i>Biochemical Pharmacology</i> , 1992, 43, 659-666.	2.0	185
72	Pharmacology of human dopamine D <sub>3</sub> receptor expressed in a mammalian cell line: comparison with D <sub>2</sub> receptor. <i>European Journal of Pharmacology</i> , 1992, 225, 331-337.	2.7	382

#	ARTICLE	IF	CITATIONS
73	The dopamine receptor family: molecular biology and pharmacology. <i>Seminars in Neuroscience</i> , 1992, 4, 99-108.	2.3	113
74	Shorter variants of the D3 dopamine receptor produced through various patterns of alternative splicing. <i>Biochemical and Biophysical Research Communications</i> , 1991, 176, 1584-1592.	1.0	118
75	Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. <i>Brain Research</i> , 1991, 564, 203-219.	1.1	825
76	Chromosomal localization of the human D3 dopamine receptor gene. <i>Human Genetics</i> , 1991, 87, 618-620.	1.8	85
77	Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. <i>Nature</i> , 1990, 347, 146-151.	13.7	2,565
78	Alternative splicing directs the expression of two D2 dopamine receptor isoforms. <i>Nature</i> , 1989, 342, 923-926.	13.7	670
79	Photoaffinity labeling of D-2 dopamine binding subunits from rat striatum, anterior pituitary and olfactory bulb with a new probe, [3H] azidosulpride. <i>Biochemical and Biophysical Research Communications</i> , 1985, 130, 1086-1092.	1.0	22
80	3H-domperidone binding sites differ in rat striatum and pituitary. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1984, 327, 221-227.	1.4	41
81	3H-apomorphine labels both dopamine postsynaptic receptors and autoreceptors. <i>Nature</i> , 1980, 288, 283-286.	13.7	103